Amgen Inc (AMGN) 159.89 $AMGN
My Dividend Portfolio: 2014 Q4 Update
Integrator - at Seeking Alpha - Sat Jan 03, 7:18AM CST
BDX: 139.86 (+0.70), GE: 25.06 (-0.21), LMT: 193.31 (+0.74), CLX: 103.87 (-0.34), HSY: 103.71 (-0.22), NKE: 95.03 (-1.12), WBK: 26.82 (-0.08), PEP: 94.44 (-0.12), SBUX: 81.44 (-0.61), CME: 88.14 (-0.51), JNJ: 104.52 (-0.05), COST: 141.61 (-0.14), BP: 38.12 (unch), MSFT: 46.76 (+0.31), CSCO: 27.61 (-0.21), YUM: 72.35 (-0.50), KO: 42.14 (-0.08), CHD: 79.09 (+0.28), COP: 68.92 (-0.14), AMGN: 159.89 (+0.60), DIS: 93.75 (-0.44), ADP: 83.29 (-0.08), CVS: 95.10 (-1.21), PG: 90.44 (-0.65), VZ: 46.96 (+0.18), CL: 69.04 (-0.15)
Final Glance: Biotechnology companies
AP - Fri Jan 02, 5:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 14.76 (-0.39), AMGN: 159.89 (+0.60), AMAG: 42.60 (-0.02)
Midday Glance: Biotechnology companies
AP - Fri Jan 02, 12:20PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Amgen Increases Dividend 30% And Has Had Lots Of Capital Appreciation During 2014
Abba's Aces - at Seeking Alpha - Fri Jan 02, 10:01AM CST
AMGN: 159.89 (+0.60)
FDA drug approvals reached 18-year high in 2014
By MATTHEW PERRONE - AP - Fri Jan 02, 9:44AM CST
WASHINGTON (AP) — The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.
AMGN: 159.89 (+0.60)
Early Glance: Biotechnology companies
AP - Fri Jan 02, 9:21AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.65 (-0.33), AMGN: 159.89 (+0.60), NVS: 92.25 (-0.41)
Dividend Champions For January 2015
David Fish - at Seeking Alpha - Thu Jan 01, 3:24AM CST
SJR: 26.82 (-0.17), GE: 25.06 (-0.21), OCR: 72.82 (-0.11), WILN: 3.02 (+0.03), DEI: 29.03 (+0.63), BLX: 30.13 (+0.03), THG: 70.67 (-0.65), VTR: 73.31 (+1.61), TEL: 63.17 (-0.08), WDR: 49.44 (-0.38), BCS: 14.92 (-0.09), BUD: 111.74 (-0.58), BMR: 21.87 (+0.33), EMN: 76.48 (+0.62), ARE: 89.79 (+1.05), WU: 17.93 (+0.02), PRA: 45.05 (-0.10), GIL: 55.92 (-0.63), PFE: 31.33 (+0.18), CUBE: 22.37 (+0.30), AHT: 10.52 (+0.04), DIS: 93.75 (-0.44), AMGN: 159.89 (+0.60), HBNC: 25.86 (-0.28), COR: 40.55 (+1.50), GLW: 23.01 (+0.08), MORN: 65.18 (+0.47), ERIE: 89.34 (-1.43), PSEC: 8.40 (+0.14), MAA: 76.15 (+1.47)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.48 (+0.16), CLDX: 18.41 (+0.16), AMGN: 159.89 (+0.60), JUNO: 48.25 (-3.97), MNKD: 5.64 (+0.42)
Epirus Biopharma: A High Risk/High Reward Biosimilar Investment
Brendan O'Boyle - at Seeking Alpha - Wed Dec 31, 5:59AM CST
PFE: 31.33 (+0.18), EPRS: 5.63 (-0.04), MYL: 56.35 (-0.02), AMGN: 159.89 (+0.60), TEVA: 56.22 (-1.29), HSP: 61.87 (+0.62)
Despite Positive Phase 3 Results, Radius Health May Warrant A Short Sale
Amit Ghate - at Seeking Alpha - Wed Dec 31, 4:00AM CST
RDUS: 41.21 (+2.30), MRK: 57.19 (+0.40), AMGN: 159.89 (+0.60), LLY: 70.06 (+1.07)
Teva's Granix Label Expanded to Include Self-Administration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:25PM CST
Teva Pharmaceutical Industries Ltd. (TEVA) announced that an additional administration option for Granix injection has been approved by the FDA.
AGN: 212.75 (+0.16), ACT: 259.13 (+1.72), AMGN: 159.89 (+0.60), TEVA: 56.22 (-1.29)
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned
Regarded Solutions - at Seeking Alpha - Tue Dec 30, 2:08PM CST
AMGN: 159.89 (+0.60), ABBV: 65.89 (+0.45), CHRS: 15.82 (-0.50)
Portfolio Changes For The Fourth Quarter Of 2014
Alexander J. Poulos - at Seeking Alpha - Tue Dec 30, 12:35PM CST
HSY: 103.71 (-0.22), C: 54.26 (+0.15), XOM: 92.83 (+0.38), GOOG: 524.81 (-1.59), CCE: 43.88 (-0.34), SLB: 85.67 (+0.26), ZROZ: 121.49 (+1.67), YHOO: 50.17 (-0.34), V: 265.02 (+2.82), IBM: 162.06 (+1.62), S: 4.24 (+0.09), DE: 88.34 (-0.13), GOOGL: 529.55 (-1.11), TMUS: 27.30 (+0.36), BK: 40.46 (-0.11), AAPL: 109.33 (-1.05), WAG: 76.05 (-0.49), REGN: 410.16 (-0.09), TMK: 54.16 (-0.01), HTZ: 25.02 (+0.08), EMN: 76.48 (+0.62), FB: 78.45 (+0.43), AMGN: 159.89 (+0.60), WFC: 54.70 (-0.12), TSM: 22.28 (-0.10), ALL: 70.12 (-0.13), ORCL: 44.33 (-0.64), TOT: 51.16 (-0.04), GILD: 94.91 (+0.65), MCD: 93.26 (-0.44), FLT: 150.26 (+1.55), VIAB: 75.40 (+0.15), VZ: 46.96 (+0.18), CTSH: 52.67 (+0.01), GIS: 53.11 (-0.22), CL: 69.04 (-0.15), CBS: 54.79 (-0.55), BABA: 103.60 (-0.34)
My Dividend Portfolio: 2014 Q4 Update
Integrator - at Seeking Alpha - Sat Jan 03, 7:18AM CST
BDX: 139.86 (+0.70), GE: 25.06 (-0.21), LMT: 193.31 (+0.74), CLX: 103.87 (-0.34), HSY: 103.71 (-0.22), NKE: 95.03 (-1.12), WBK: 26.82 (-0.08), PEP: 94.44 (-0.12), SBUX: 81.44 (-0.61), CME: 88.14 (-0.51), JNJ: 104.52 (-0.05), COST: 141.61 (-0.14), BP: 38.12 (unch), MSFT: 46.76 (+0.31), CSCO: 27.61 (-0.21), YUM: 72.35 (-0.50), KO: 42.14 (-0.08), CHD: 79.09 (+0.28), COP: 68.92 (-0.14), AMGN: 159.89 (+0.60), DIS: 93.75 (-0.44), ADP: 83.29 (-0.08), CVS: 95.10 (-1.21), PG: 90.44 (-0.65), VZ: 46.96 (+0.18), CL: 69.04 (-0.15)
Final Glance: Biotechnology companies
AP - Fri Jan 02, 5:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Tekmira Jumped Following Update on its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:20PM CST
Tekmira Pharmaceuticals' (TKMR) shares increased almost 9% after it provided updates from phase I/II studies on TKM-PLK1.
TKMR: 14.76 (-0.39), AMGN: 159.89 (+0.60), AMAG: 42.60 (-0.02)
Midday Glance: Biotechnology companies
AP - Fri Jan 02, 12:20PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Amgen Increases Dividend 30% And Has Had Lots Of Capital Appreciation During 2014
Abba's Aces - at Seeking Alpha - Fri Jan 02, 10:01AM CST
AMGN: 159.89 (+0.60)
FDA drug approvals reached 18-year high in 2014
By MATTHEW PERRONE - AP - Fri Jan 02, 9:44AM CST
WASHINGTON (AP) — The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.
AMGN: 159.89 (+0.60)
Early Glance: Biotechnology companies
AP - Fri Jan 02, 9:21AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Acute Heart Failure - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4c2c74/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute heart failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute heart failure and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute heart failure - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute heart failure pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. - Nyken BV - Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4c...cute_heart
TRVN: 5.65 (-0.33), AMGN: 159.89 (+0.60), NVS: 92.25 (-0.41)
Dividend Champions For January 2015
David Fish - at Seeking Alpha - Thu Jan 01, 3:24AM CST
SJR: 26.82 (-0.17), GE: 25.06 (-0.21), OCR: 72.82 (-0.11), WILN: 3.02 (+0.03), DEI: 29.03 (+0.63), BLX: 30.13 (+0.03), THG: 70.67 (-0.65), VTR: 73.31 (+1.61), TEL: 63.17 (-0.08), WDR: 49.44 (-0.38), BCS: 14.92 (-0.09), BUD: 111.74 (-0.58), BMR: 21.87 (+0.33), EMN: 76.48 (+0.62), ARE: 89.79 (+1.05), WU: 17.93 (+0.02), PRA: 45.05 (-0.10), GIL: 55.92 (-0.63), PFE: 31.33 (+0.18), CUBE: 22.37 (+0.30), AHT: 10.52 (+0.04), DIS: 93.75 (-0.44), AMGN: 159.89 (+0.60), HBNC: 25.86 (-0.28), COR: 40.55 (+1.50), GLW: 23.01 (+0.08), MORN: 65.18 (+0.47), ERIE: 89.34 (-1.43), PSEC: 8.40 (+0.14), MAA: 76.15 (+1.47)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.48 (+0.16), CLDX: 18.41 (+0.16), AMGN: 159.89 (+0.60), JUNO: 48.25 (-3.97), MNKD: 5.64 (+0.42)
Epirus Biopharma: A High Risk/High Reward Biosimilar Investment
Brendan O'Boyle - at Seeking Alpha - Wed Dec 31, 5:59AM CST
PFE: 31.33 (+0.18), EPRS: 5.63 (-0.04), MYL: 56.35 (-0.02), AMGN: 159.89 (+0.60), TEVA: 56.22 (-1.29), HSP: 61.87 (+0.62)
Despite Positive Phase 3 Results, Radius Health May Warrant A Short Sale
Amit Ghate - at Seeking Alpha - Wed Dec 31, 4:00AM CST
RDUS: 41.21 (+2.30), MRK: 57.19 (+0.40), AMGN: 159.89 (+0.60), LLY: 70.06 (+1.07)
Teva's Granix Label Expanded to Include Self-Administration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:25PM CST
Teva Pharmaceutical Industries Ltd. (TEVA) announced that an additional administration option for Granix injection has been approved by the FDA.
AGN: 212.75 (+0.16), ACT: 259.13 (+1.72), AMGN: 159.89 (+0.60), TEVA: 56.22 (-1.29)
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned
Regarded Solutions - at Seeking Alpha - Tue Dec 30, 2:08PM CST
AMGN: 159.89 (+0.60), ABBV: 65.89 (+0.45), CHRS: 15.82 (-0.50)
Portfolio Changes For The Fourth Quarter Of 2014
Alexander J. Poulos - at Seeking Alpha - Tue Dec 30, 12:35PM CST
HSY: 103.71 (-0.22), C: 54.26 (+0.15), XOM: 92.83 (+0.38), GOOG: 524.81 (-1.59), CCE: 43.88 (-0.34), SLB: 85.67 (+0.26), ZROZ: 121.49 (+1.67), YHOO: 50.17 (-0.34), V: 265.02 (+2.82), IBM: 162.06 (+1.62), S: 4.24 (+0.09), DE: 88.34 (-0.13), GOOGL: 529.55 (-1.11), TMUS: 27.30 (+0.36), BK: 40.46 (-0.11), AAPL: 109.33 (-1.05), WAG: 76.05 (-0.49), REGN: 410.16 (-0.09), TMK: 54.16 (-0.01), HTZ: 25.02 (+0.08), EMN: 76.48 (+0.62), FB: 78.45 (+0.43), AMGN: 159.89 (+0.60), WFC: 54.70 (-0.12), TSM: 22.28 (-0.10), ALL: 70.12 (-0.13), ORCL: 44.33 (-0.64), TOT: 51.16 (-0.04), GILD: 94.91 (+0.65), MCD: 93.26 (-0.44), FLT: 150.26 (+1.55), VIAB: 75.40 (+0.15), VZ: 46.96 (+0.18), CTSH: 52.67 (+0.01), GIS: 53.11 (-0.22), CL: 69.04 (-0.15), CBS: 54.79 (-0.55), BABA: 103.60 (-0.34)
